
We welcome you to the TBnet monthly webinar on the 24th of February @ 16 CET!
In this webinar, therapeutic drug monitoring in tuberculosis will be discussed during the keynote lecture and case presentation.
Join us on Zoom!
Time: February 24, 2022 at 16 PM (CET)
Meeting ID: 932 7615 3966 Passcode: 685319
Speakers:
Prof. Rob Aarnoutse, PharmD PhD, Radboud University Medical Center, Nijmegen, the Netherlands.
Rob Aarnoutse studied Pharmacy in Utrecht and was trained as a hospital pharmacist at the Albert Schweitzer hospital in Dordrecht, The Netherlands. Since 1999 he has been working at Radboudumc. In 2003 he obtained a PhD title based on his thesis ‘Application of pharmacokinetics to improve antiretroviral treatment’. Besides his research activities, he is actively involved in patient care as a hospital pharmacist, dedicated as a trainer for hospital pharmacy trainees, and trainer for clinical pharmacology at Radboudumc. Internationally he is a member of the chief investigators group of the PanACEA TB research consortium, initiated the leading annual meeting in the TB pharmacology field, and started several international proficiency testing programmes for the measurement of drugs in blood.
Therapeutic drug monitoring (TDM) is the concept of individualizing drug dosing by measuring the drug concentration in a patient's serum/plasma and adjusting the dose accordingly. This lecture focuses on the rationale for TDM of TB drugs, the criteria for TDM to be useful, the actual TDM practice for TB drugs and new developments. The case will be made that TDM can be a decisive tool in TB treatment, but some limitations need to be considered.
Niklas Köhler, MD, is a project coordinator and doctoral candidate in the Laboratory of Professor Christoph Lange at the Research Center Borstel, Borstel, Germany.
Since 2015, he has been implementing therapeutic drug monitoring as a tool for personalized medicine at the medical clinic of the Research Center Borstel. He has worked in the development of an HPLC-MS platform and set up a network of international partner laboratories and pharmacology experts to advise the clinic team on difficult-to-treat patients. Recently graduated from med school, he now works as a medical project coordinator in Romanian-German cooperation to advance cross-border patient care.
Expert panel:
Liga Kuksa MD, Riga East University Hospital, Riga, Latvia
Ass. Prof. Dumitru Chesov MD PhD, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova
Gunar Günther MD PhD, Inselspital Bern, Berne, Switzerland.
Chair:
Prof. Dr. med. Dr. h.c. Christoph Lange, Research Center Borstel, Germany.

Comentarios